Clinical trials: Recompensation
Cirrhosis
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease.
- Trial name
- NCT07652203
- Testing
- conventional therapy, propranolol
- Where
- China
- Volunteers
- 466 people
- Sponsor
- General Hospital of Shenyang Military Region
Hepatic Cirrhosis, Portal Hypertension
The Treatment of Hepatocirrhosis and Portal Hypertension
This study compare the efficiency of partial splenic embolization +endoscopical therapy with endoscopical therapy alone in gastroesophageal variceal haemorrhage accompanied with splenomegaly or hypersplenism of hepatocirrhosis…
- Trial name
- NCT02778425
- Testing
- Endoscopic therapy+ beta blockers, Endoscopic therapy+ PSE+beta blockers, beta blockers
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Yanjing Gao
Liver Failure
Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure
The objective of this trial is to evaluate the impact of elimination of albumin bound substances during albumin dialysis (MARS®) on mortality and the clinical time course in patients with a recent severe clinical deterioration of…
- Trial name
- RELIEF (NCT00614146)
- Testing
- MARS device, Standard medical therapy
- Where
- 19 sites in Austria, Belgium and 7 more
- Volunteers
- 59 people
- Sponsor
- Vantive Health LLC
Decompensated Cirrhosis
Risk Stratification for Adverse Events in End-Stage Liver Disease
Study Goal The goal of this multicenter, prospective observational cohort study is to develop and validate a multimodal predictive model that integrates portal hypertension, inflammation, and liver function indicators to predict…
- Trial name
- D-TECT (NCT07880678)
- Testing
- Routine Clinical Care with Biospecimen Collection and Free MRE Testing
- Volunteers
- 2,235 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of…
- Conditions
- Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
- Trial name
- LEAD-2 (NCT07087041)
- Where
- 28 sites in China
- Volunteers
- 735 people
- Sponsor
- Beijing Friendship Hospital
Heart Failure, Telemonitoring
EXPLORATORY STUDY OF THE MYHEARTSENTINEL SYSTEM, A CARDIAMETRICS MEDICAL DEVICE
Background: Chronic heart failure represents a major public health challenge, affecting approximately 64 million people worldwide and generating high costs in terms of mortality, frequent hospitalizations, and medical expenses.
- Conditions
- Heart Failure, Telemonitoring, Right Heart Catheterisation
- Trial name
- ASEMC-DR (NCT07345533)
- Testing
- MYHEARTSENTINEL SYSTEM cutaneous DEVICE
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Caen
Cirrhosis, Decompensation
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
The traditional view holds that the natural course of cirrhosis is a unidirectional process, characterized by irreversible progression from the compensated stage to the decompensated stage, and is highly likely to develop further…
- Conditions
- Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
- Trial name
- NCT07172035
- Where
- 15 sites in China
- Volunteers
- 250 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Decompensated Cirrhosis
Incidence & Predictive Factors of Recompensation in Children With Decompensated Cirrhosis as Per the Baveno VII Criteria
Cirrhosis is a leading cause of morbidity and mortality world- wide and can develop on the basis of repetitive and/or chronic liver injury due to toxic, infectious, metabolic and genetic pathogenic factors.
- Trial name
- NCT06344611
- Testing
- Other
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cardiac Recompensation
Not Invasive Monitoring at Cardiac Recompensation
The aim of this study is to find out if data can be provided by external sensor technology which is suitable for controlling the therapy of patients with cardiac recompensation.
- Trial name
- NCT01775306
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- RWTH Aachen University
Heart Failure, Cognitive Impairment
Cognitive Impairment in Patients With Heart Failure
The aim of the present study is threefold: investigating 1) specific cognitive impairments in patients with congestive heart failure, 2) whether cognitive impairments in patients with decompensated heart failure improve after…
- Trial name
- CogImpairHF (NCT00837889)
- Testing
- diuretics, inotropica
- Where
- 2 sites in Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Alcoholic Hepatitis (AH)
Recompensation in Alcohol Related Hepatitis
Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism.
- Trial name
- A-HEP (NCT06740318)
- Testing
- Motivational enhancement therapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Nina Kimer